Article
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
European journal of gastroenterology & hepatology - 1 Nov 2017
Dolmazashvili Ekaterine, Abutidze Akaki, Chkhartishvili Nikoloz, Karchava Marine, Sharvadze Lali, Tsertsvadze Tengiz
Abstract excerpt
OBJECTIVE: We assessed the impact of direct-acting antiviral (DAA) therapy on liver fibrosis regression measured by transient elastography (TE) in patients with chronic hepatitis C virus (HCV) infection. PATIENTS AND METHODS: A prospective cohort study was carried out in HCV monoinfected patients with advanced liver fibrosis or cirrhosis receiving interferon (IFN)-containing or IFN-free DAA therapy. Liver...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.